Patents by Inventor Tracy STATON

Tracy STATON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20240410009
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: August 26, 2024
    Publication date: December 12, 2024
    Applicant: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20240368306
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: February 13, 2024
    Publication date: November 7, 2024
    Inventors: Xiaocheng CHEN, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • Gene expression markers and treatment of multiple sclerosis
    Patent number: 12098426
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS
    Publication number: 20240124937
    Abstract: The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the IL1RL1 gene. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the IL1RL1 gene.
    Type: Application
    Filed: June 6, 2023
    Publication date: April 18, 2024
    Inventors: Rajita KHOSLA, Vladimir RAMIREZ-CARROZZI, Tracy STATON, Brian YASPAN, Joseph ARRON, David CHOY, Amy DRESSEN
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 11939396
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • Therapeutic and diagnostic methods for IL-33-mediated disorders
    Patent number: 11708608
    Abstract: The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the /L1RL1gene, the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the /L1RL1gene the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 25, 2023
    Assignee: Genentech, Inc.
    Inventors: Rajita Khosla, Vladimir Ramirez-Carrozzi, Tracy Staton, Brian Yaspan, Joseph Arron, David Choy, Amy Dressen
  • GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20220098668
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Applicant: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Gene expression markers and treatment of multiple sclerosis
    Patent number: 11236391
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20200325248
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 15, 2020
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 10752703
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: August 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 10738131
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: August 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20190367637
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20180230233
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 16, 2018
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS
    Publication number: 20180171405
    Abstract: The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the /L1RL1gene, the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the /L1RL1gene the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2.
    Type: Application
    Filed: November 10, 2015
    Publication date: June 21, 2018
    Inventors: Rajita KHOSLA, Vladimir RAMIREZ-CARROZZI, Tracy STATON, Brian YASPAN, Joseph ARRON, David CHOY, Amy DRESSEN
  • GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20180080080
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: MICHAEL TOWNSEND, ALVERNIA FRANCESCA SETIADI, TRACY STATON
  • THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS
    Publication number: 20160168640
    Abstract: The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the IL1RL1 gene. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the IL1RL1 gene.
    Type: Application
    Filed: November 10, 2015
    Publication date: June 16, 2016
    Inventors: Rajita KHOSLA, Vladimir RAMIREZ-CARROZZI, Tracy STATON, Brian YASPAN, Joseph ARRON, David CHOY, Amy DRESSEN